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Abstract
OBJECTIVE: To test the synergistic effects of the
aqueous extract of Tubeimu (Rhizoma Bolbostem-
matis) and Fuzi (Radix Aconiti Lateralis Preparata) on
MDA-MB-231 and SKBR3 breast cancer cells.
METHODS: A combined index was created for the
effects of Tubeimu (Rhizoma Bolbostemmatis) and
Fuzi (Radix Aconiti Lateralis Preparata) extracts. Cell
proliferation was performed by trypan blue exclu-
sion and 3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assays. Flow cytometry was used to assess
cell cycle distribution and apoptosis. Cell migration
was determined by wound-healing and transwell
assays. Confocal microscopy was used to detect
E-cadherin and actin filaments.
RESULTS: The aqueous extract from Tubeimu (Rhi-
zoma Bolbostemmatis) and Fuzi (Radix Aconiti Later-
alis Preparata) exerted synergetic effects on the
growth of MDA-MB-231 cells and G1 phase arrest.
When exposed to extracts at concentrations of 62.5
∶62.5 and 62.5∶31.3 µg/mL, the combination index
was 0.83 and 0.74, respectively. Interestingly, 62.5∶
31.3 µg/mL of combined drugs enhanced the inhib-
itory effect of Tubeimu (Rhizoma Bolbostemmatis)
on the migration of SKBR3 cells and reduced the
stimulative effect of Fuzi (Radix Aconiti Lateralis Pre-
parata) (P < 0.01), in which cells showed an in-
creased expression of E-cadherin and reorganiza-
tion of actin filaments (P < 0.001). 62.5∶62.5 µg/mL
extract also synergistically induced apoptosis of
MDA-MB-231 cells (P < 0.05 and P < 0.001). Acting
as the main active ingredients in the extract, tubei-
moside I and acetylbenzoylaconine at 10∶10 µg/
mL and 5∶2.5 µg/mL also produced inhibitory ef-
fects on the proliferation and migration of cells (P <
0.01).
CONCLUSION: Tubeimu (Rhizoma Bolbostemmatis)
and Fuzi (Radix Aconiti Lateralis Preparata) extracts
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had synergic effects on MDA-MB-231 and SKBR3
cells.
© 2016 JTCM.
Key words: Radix Aconiti Lateralis Preparata; Bolb-
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Breast neoplasms; MDA-MB-231; SKBR3
INTRODUCTION
Traditional Chinese Medicine (TCM) has been used to
treat various diseases for more than 2500 years. Based
on TCM theory, we designed a warming and relieving
cold phlegm formula (WRCP), composed of Fuzi (Ra-
dix Aconiti Lateralis Preparata), Tubeimu (Rhizoma Bol-
bostemmatis), Shanglu (Radix Phytolaccae), Sanqi (Ra-
dix Notoginseng), and Bihu (Gekko Swinhonis). WRCP
was shown to have direct anti-cancer effects in vitro
and in vivo. In a human breast MDA-MB-231 xeno-
graft model, WRCP could effectively inhibit tumor
growth and induce tumor necrosis without changing
body weight or organ indexes.3,4 Aconitum was previ-
ously shown to have antitumor activity.5 Tubeimu (Rhi-
zoma Bolbostemmatis) has been used to treat breast can-
cer for more than 270 years in TCM.6 A recent study
indicated that Tubeimu (Rhizoma Bolbostemmatis)
could induce apoptosis in the human breast cancer cell
line MDA-MB-231.7 Tubeimoside I and acetylbenzo-
ylaconine, the respective major active ingredients of Tu-
beimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Acon-
iti Lateralis Preparata), also showed antitumor activities
in several cancer cell lines.8-11 These results suggest pos-
sible synergistic effects between Tubeimu (Rhizoma Bol-
bostemmatis) and Fuzi (Radix Aconiti Lateralis Prepara-
ta). Here, we aimed to explore the effect of Tubeimu
(Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Late-
ralis Preparata) on MDA-MB-231 and SKBR3 breast
cancer cells.
MATERIALS ANDMETHODS
Herbs and preparation of aqueous extracts
Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix
Aconiti Lateralis Preparata) were obtained from the
Manufacturing and Distributing Branch of the Sich-
uan Chinese Herb Company on January 8, 2012
(Xi-er-duan, Yi-an-lu, Chengdu, China). The herbs
were authenticated by Dr. Wu Jun-Qing at Si-Yang
Medical Institute of Meishan. A voucher specimen
(No. 20120108) was deposited in the Zhong-Shan-
Men Inpatient Department of the Tianjin Medical Uni-
versity Cancer Institute and Hospital.
Whole herbs of Tubeimu (Rhizoma Bolbostemmatis)
and Fuzi (Radix Aconiti Lateralis Preparata) (100 g
each) were ground into powder and extracted twice
with hot distilled water (1000 and 800 mL, respective-
ly) at 100 ℃ for 30 min. The solutions were combined
and centrifuged at 2.2 g for 10 min. The resulting su-
pernatant was filtered, concentrated, and dried to ob-
tain residue (Fuzi: 36.01 g and Tubeimu: 34.03 g). The
residue was dissolved in phosphate buffered saline at a
concentration of 10 mg/mL and stored at －20 ℃ as
the stock extract solution.
Cell culture and reagents
MDA-MB-231 and SKBR3 breast cancer cell lines
were obtained from Tianjin Medical University Can-
cer Institute and Hospital (Tianjin, China).
MDA-MB- 231 cells were cultured in Leibovitz's
L-15 medium (Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Hy-
clone, Logan, UT, USA) in a free gas exchange with
atmospheric air. SKBR3 cells were cultured in
DMEM medium (Hyclone, Logan, UT, USA) supple-
mented with 10% fetal bovine serum at 37 ℃ in a
humidified 5% CO2 incubator.
Trypan blue exclusion assay
MDA-MB-231 cells were seeded at 1×104 cells/well in
24-well plates (Corning, NY, USA). Cells were collect-
ed 48 h after treatment with Tubeimu (Rhizoma Bolb-
ostemmatis) at 15.6-500 µg/mL, Fuzi (Radix Aconiti
Lateralis Preparata) at 15.6-500 µg/mL or the combina-
tion of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi
(Radix Aconiti Lateralis Preparata) at the weight ratio of
1∶1, 2∶1, or 1∶2. The trypan blue exclusion assay was
used to determine viable and total cell numbers. This
method offers quantitative definitions for antagonism,
additive effect and synergism in drug combinations
and is widely used in drug combination studies.1,12-14 Fa
is the fraction affected, where 1 is equivalent to 100%
inhibition. Combination index (CI) was calculated us-
ing the CI-isobologram method based on data derived
from cells treated with single drugs and drug combina-
tions at the indicated weight ratios and plotted versus
Fa. A CI value of less than, equal to, or more than 1 in-
dicate synergistic, additive, and antagonistic effects, re-
spectively. CI values were calculated using the equa-
tion: CI = (D)1/(Dx)1 + (D)2/(Dx)2. (Dx)1 and (Dx)
2 are the concentrations of Fuzi (Radix Aconiti Lateralis
Preparata) and Tubeimu (Rhizoma Bolbostemmatis)
alone at x% growth inhibition. (D)1 and (D)2 are the
concentrations of the drugs in combination at x%
growth inhibition. (Dx)1 and (Dx)2 were calculated us-
ing the median-effect equation: Dx = Dm(Fa/[1 − Fa])
1/m. Dm is the median-effect dose and m is the slope
of the median-effect plot.
The percentage of cell survival was calculated as fol-
lows: percentage of cell survival (%) = (mean viable cell
number/mean total cell number) × 100%. Morphologi-
cal variations of the cells were observed by optical mi-
croscopy at 48 h after drug treatment.
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MTS assay
1×103 SKBR3 cells in 100 µL of culture medium were
seeded in each well of a 96-well plate. Cells were then
divided into tubeimoside I (Bellancom, Beijing, Chi-
na) groups (3-10 µg/mL), acetylbenzoylaconine (Bel-
lancom) groups (1.5-20 µg/mL), and combination
groups at weight ratios of 1∶1, 2∶1, or 1∶2. Tubeimo-
side I and acetylbenzoylaconine, are the respective ma-
jor ingredients of Tubeimu (Rhizoma Bolbostemmatis)
and Fuzi (Radix Aconiti Lateralis Preparata) (Figure 1).
At 44 h after drug treatment, 20-µL MTS reagent (Pro-
mega, Madison, WI, USA) was pipetted into each well
of the 96-well plate. The plate was then incubated at
37 ℃ for 4 h and the optical density (OD) values were
recorded at 490 nm.
Flow cytometry analysis
MDA-MB-231 and SKBR3 cells were seeded at 3 ×
104－1× 105 cells/well in 6-well plates. Cells were col-
lected 48 h after adding Tubeimu (Rhizoma Bolbostem-
matis) (62.5 µg/mL) and/or Fuzi (Radix Aconiti Latera-
lis Preparata) (62.5 µg/mL). As2O3 was used as a posi-
tive control. To detect apoptosis in early and later stag-
es, cells were stained with FITC Annexin V and PI
(BD Biosciences, Franklin Lakes, NJ, USA), respective-
ly. For cell cycle analysis, cells were fixed with 75% eth-
anol and stained with PI alone (50 µg/mL). Apoptosis
and DNA distribution were analyzed by flow cytome-
try (BD FACSCalibur, Franklin Lakes, NJ, USA).
Enzyme-linked immunosorbent assay
MDA-MB-231 cells were seeded at 3 × 104 cells/well in
12-well plates. After 24 h, the culture medium was re-
placed with medium containing Tubeimu (Rhizoma
Bolbostemmatis) (62.5 µg/mL) and/or Fuzi (Radix Acon-
iti Lateralis Preparata) (62.5 µg/mL). Cells were then
incubated an additional 72 h. The cell monolayers
were then lysed with 100 µL of RIPA buffer for 30 min,
collected, and centrifuged at 9.0 × g for 5 min at 4 ℃.
The supernatants were collected and the concentration
of aquaporin (AQP) 1 was measured using AQP1 en-
zyme-linked immunosorbent assay kit (Dongge, Bei-
jing, China) according to the manufacturer's instruc-
tions.
Wound-healing assay
MDA-MB-231 and SKBR3 cells were serum-starved
for 24 h then seeded at 1 × 105 cells/well in 24-well
plate. After 24 h, a linear wound approximately 1 mm
in width was made by scratching the monolayer cell
culture with a pipette tip. For cell growth, 2% FBS of
culture medium containing Tubeimu (Rhizoma Bolb-
ostemmatis) (62.5 µg/mL), Fuzi (Radix Aconiti Lateralis
Preparata) (62.5, 31.3 µg/mL), or combined drugs
(62.5∶62.5 or 62.5∶31.3 µg/mL) were added. Cell mi-
gration was observed under a phase-contrast micro-
scope and expressed as the spacing of scarification at 0
and 12 h after exposure to drugs.
Transwell assays
MDA-MB-231 and SKBR3 cells were serum-starved
for 24 h and resuspended in serum-free culture medi-
um. Approximately 5 × 104 cells were seeded into each
upper transwell chamber (Millipore, Boston, MA,
USA), while the lower chambers were supplemented
with 10% FBS of culture medium as well as Tubeimu
(Rhizoma Bolbostemmatis) (62.5 µg/mL) and/or Fuzi
(Radix Aconiti Lateralis Preparata) (62.5, 31.3 µg/mL).
To determine the effect of the active ingredients of Tu-
beimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Acon-
iti Lateralis Preparata) on cell migration, lower cham-
bers were supplemented with tubeimoside I (3-10 µg/
mL) and/or acetylbenzoylaconine (3-10 µg/mL). Cells
were then incubated at 37 ℃ for 12 h, at which point
cells on the inner surface of the upper chamber were re-
moved. Cells that penetrated through the chamber
were fixed, stained with crystal violet (0.1%), and count-
ed using a light microscope (Olympus, Tokyo, Japan).
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Figure 1 Chemical structure of acetylbenzoylaconine and tubeimoside I
A: Acetylbenzoylaconine, formula: C34H47NO11, molecular weight: 645.74; B: tubeimoside I, formula: C63H98O29, molecular weight:
1319.46.
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Confocal microscopy
SKBR3 cells were serum-starved for 24 h and seeded at
1 × 105 cells/well in 6-well plates. Cells were then divid-
ed into the Tubeimu (Rhizoma Bolbostemmatis) group
at 62.5 µg/mL, Fuzi (Radix Aconiti Lateralis Preparata)
group at 62.5 µg/mL, and combination groups of Tu-
beimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Acon-
iti Lateralis Preparata) at 62.5∶62.5 and 62.5∶31.3 µg/
mL. Twelve hours after drug treatment, cells were first
incubated with an antibody against E-cadherin (Ab-
cam, Cambridge, UK) at 1∶100 for 16 h at 4 ℃ , fol-
lowed by incubation with a fluorescence-conjugated
secondary antibody (1∶5000) at room temperature for
1 h. To determine the localization and configuration of
actin filaments, the cells cultured on coverslips were
fixed with 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100. Cells were incubated with
1% bovine serum albumin and 2-µg/mL phalloidin
rhodamine (Enzo Life Sciences, New York, NY, USA)
at 4 ℃ overnight, followed by staining with 4′ ,6-di-
amidino-2-phenylindole (1 µg/mL). Immunostained
cells were mounted using antifade mounting medium
and examined using a confocal microscope (Leica,
Dresden, Germany). The fluorescence of E-cadherin
was quantified as integral optical density.
Statistical analysis
Single-factor analysis of variance was used for data anal-
ysis. P < 0.05 was considered statistically significant.
Statistical calculations were performed by statistical
software SPSS 16.0 (SPSS, Chicago, IL, USA). All val-
ues are expressed as the mean ± standard deviation ( xˉ
± s).
RESULTS
Effect of the extract on cell proliferation and cell
cycle distribution
Our data showed that Tubeimu (Rhizoma Bolbostemma-
tis) extract at 15.6-500 µg/mL effectively inhibited the
proliferation of MDA-MB-231 cells, while Fuzi (Radix
Aconiti Lateralis Preparata) extract at 15.6-500 µg/mL
had no influence on proliferation. The CIs of the com-
bined treatments of the two extracts at 1∶1 and 2∶1
weight ratios were less than 1 at every Fa level ranging
from 0.1 to 0.9, indicating synergic effects. However,
the CI of the combined extracts at 1∶2 was more than
1, indicating antagonistic effects. The dose of com-
bined treatment of the two extracts was less than those
of either individual extract while reaching the same Fa
(Table 1). Furthermore, after exposure to combined
treatment of the two extract concentrations, 62.5∶
62.5 µg/mL and 62.5∶31.3 µg/mL, the Fa values were
79.72% and 82.23% and the CI values were 0.83 and
0.74, respectively (Figure 2A).
In the MTS assay, tubeimosideⅠ at 3-7 µg/mL, acetyl-
benzoylaconine at 1.5-20 µg/mL, and control had no
effects on the proliferation of SKBR3 cells. Tubeimo-
side Ⅰ at 10 µg/mL effectively inhibited cell prolifera-
tion comparedwith the control group (P < 0.05). The
inhibitory effects of combined tubeimoside Ⅰ and
acetylbenzoylaconine treatment on cell proliferation at
10∶10 µg/mL and 10∶20 µg/mL were superior to that
of tubeimoside Ⅰ treatment at 10 µg/mL (P < 0.01,
P < 0.05, respectively). Furthermore, the inhibitory ef-
fect of combined treatment at 10∶10 µg/mL was great-
er than that of 10∶20 µg/mL (P < 0.01) (Figure 2B).
Fuzi (Radix Aconiti Lateralis Preparata) at 62.5 µg/mL
did not influence the cell cycle distribution in
MDA-MB-231 cells, while Tubeimu (Rhizoma Bolb-
ostemmatis) at 62.5 µg/mL increased the percentage of
G1-phase cells, compared with the control group (P <
0.05). The percentage of G1-phase cells in the Tubeimu
(Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Late-
ralis Preparata) combined treatment group at 62.5∶
62.5 µg/mL was much higher than those in the groups
treated with the two extracts alone (Figure 3). An obvi-
ous apoptosis peak before G1 in the combined treat-
ment group was observed, which is consistent with
that observed in the apoptosis assay (Figure 5A).
Effects of both extractions on cell viability
The Fuzi (Radix Aconiti Lateralis Preparata) extraction
had no effect on cell survival rate, cell damage, or
AQP1 expression in MDA-MB-231 cells. Meanwhile,
the MDA-MB-231 cells became tumid, accompanied
by abundant cytoplasmic vacuoles in the cytoplasm,
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(%)
99.53
99.53
98.58
91.79
79.72
62.74
25.47
RB
(µg/mL)
710.30
710.30
374.35
130.05
71.05
43.53
17.32
RALP
(µg/mL)
229051970.36
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26072842.32
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92827.00
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RB and RALP
(µg/mL)
1000∶1000
500∶500
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31.3∶31.3
15.6∶15.6
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RB and RALP
(µg/mL)
1000∶500
500∶250
250∶125
125∶62.5
62.5∶31.3
31.3∶16.5
15.6∶7.8
Table 1 Dose comparison of single drug and combined drugs when reaching same Fa
Notes: drug unit: µg/mL. Fa: Fractions affected; RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi (Radix Aconiti Lateralis Preparata).
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Figure 2 Effect of Tubeimu (Rhizoma Bolbostemmatis) and/or
Fuzi (Radix Aconiti Lateralis Preparata) on cell proliferation
A: Effect of [Tubeimu (Rhizoma Bolbostemmatis), RB] and [Fuzi
(Radix Aconiti Lateralis Preparata), RALP] on MDA-MB-231 cells.
A1: Fa treated with RB or RALP alone. MDA-MB-231 cells were
collected 48 h after treatment with RB at 15.6-500 µg/mL,
RALP at 15.6-500 µg/mL. The trypan blue exclusion assay was
used to determine viable and total cell numbers. Fa is the frac-
tion affected, where 1 is equivalent to 100% inhibition. A2: Fa
treated with the combination of RB and RALP. The method was
same as that of A1. The administration of drugs was combina-
tion of RB and RALP at the weight ratio of 1∶1, 2∶1, or 1∶2. A3:
CIs plotted versus Fa. CIwas calculatedusing theCI-isobologram
method based on data derived from cells treated with single
drugs and drug combinations at the indicated weight ratios
and plotted versus Fa. B: Effects of tubeimoside I (T) and acetylbenzoylaconine (A) on SKBR3 cells. B1: SKBR3 cells were seeded
and were treated with drugs of T at 3µg/mL and/or A at 1.5-6 µg/mL for 48 h respectively. MTS reagent was used to detect opti-
cal density at 490 nm. B2-B4: the method was same as that of B1. B2: the administration of drugs was T at 5µg/mL and/or A at
2.5-10 µg/mL. B3: the administration of drugs was T at 7 µg/mL and/or A at 3.5-14 µg/mL. B4: the administration of drugs was T
at 10µg/mL and/or A at 5-20 µg/mL. Compared with the control group, aP < 0.05; compared with A (5, 10, 20) group, bP < 0.01;
compared with A (5, 10, 20) group, cP < 0.001; compared with T (10) group, dP < 0.01; compared with T∶A (10∶20), eP < 0.01; com-
pared with T (10) group, fP < 0.05.
A3
RB Does（µg/mL)
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and increased expression of AQP1 in the Tubeimu
(Rhizoma Bolbostemmatis) extract group and the group
treated with both extracts (Figure 4A, C). However,
there was no difference in viability of MDA-MB-231
cells among all groups (P > 0.05) (Figure 4B). Similar
results were observed in SKBR3 cells.
Effects of the two extracts on apoptosis
Although the Fuzi (Radix Aconiti Lateralis Preparata)
extract at 62.5 and 31.3 µg/mL did not induce apopto-
sis of MDA-MB-231 cells, Tubeimu (Rhizoma Bolb-
ostemmatis) extract at 62.5 µg/mL effectively induced
apoptosis compared with untreated controls and the
As2O3 positive control. The apoptotic rate following
treatment with both extracts at 62.5∶62.5 µg/mL was
much higher than that in the Tubeimu (Rhizoma Bolb-
ostemmatis) extract group, which indicated synergistic
induction of apoptosis (P < 0.05). Though the apopto-
sis rate of SKBR3 cells increased from 3.12 ± 0.69 [Tu-
beimu (Rhizoma Bolbostemmatis) extract-treated group]
to 8.33 ± 1.64 or 5.63 ± 1.76 [Fuzi (Radix Aconiti Late-
ralis Preparata) group treated with both extracts], no
significance was observed (Figure 5).
Effects of the two extracts on cell migration
The Tubeimu (Rhizoma Bolbostemmatis) extract at
62.5 µg/mL down-regulated the migration of MDA-
MB- 231 and SKBR3 cells, while the Fuzi (Radix Acon-
iti Lateralis Preparata) extract at 62.5 and 31.3 µg/mL
up-regulated migration, compared with the control.
Treatment with both Tubeimu (Rhizoma Bolbostemma-
tis) and Fuzi (Radix Aconiti Lateralis Preparata) at 62.5∶
62.5 µg/mL and 62.5∶31.3 µg/mL down-regulated the
migration of MDA-MB-231 and SKBR3 cells, com-
pared with the group only treated with Fuzi (Radix
Aconiti Lateralis Preparata) extract (Figure 6). There
was no difference in cell migration between the com-
bined Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Ra-
dix Aconiti Lateralis Preparata) groups and the Tu-
beimu (Rhizoma Bolbostemmatis) group in MDA-MB-
231 cells. Interestingly, concomitant treatment with Tu-
beimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Acon-
iti Lateralis Preparata) (62.5∶31.3 µg/mL) exerted a
synergistic effect that effectively enhanced the inhibito-
ry effect of Tubeimu (Rhizoma Bolbostemmatis) on SK-
BR3 cell migration (Figure 6M right, P < 0.001; Fig-
ure 7A left, P < 0.01).
In the study of main active ingredients of Tubeimu
(Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Late-
ralis Preparata), combined tubeimoside I and acetylben-
zoylaconine treatment at 3∶1.5 µg/mL and 5∶2.5 µg/mL
in SKBR3 cells and 5∶ 2.5 µg/mL in MDA-
30MB-231 cells, also exerted synergistic inhibitory ef-
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Figure 3 Effect of Tubeimu (Rhizoma Bolbostemmatis) and/or Fuzi (Radix Aconiti Lateralis Preparata) on cell cycle
MDA-MB-231 cells were collected 48 h after treated with different drugs. A: L-15 medium; B: RALP at 62.5 µg/mL; C: RB at 62.5 µg/
mL; D: RALP: RB at 62.5∶62.5 µg/mL. Cells were fixed and stained with PI alone (50 µg/mL). Arabic numbers represent the percent-
age of cells distributed in the G1 phase. RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi (Radix Aconiti Lateralis Preparata).
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Figure 4 Effects of Tubeimu (Rhizoma Bolbostemmatis) and/or Fuzi (Radix Aconiti Lateralis Praeparata) treatment on cell survival
A: cell microphotography (× 100). MDA-MB-231 cells were treated with different drugs for 48 h. A1; L-15 culture medium; A2:
RALP at 62.5 µg/mL; A3: RALP at 31.3 µg/mL; A4: RB at 62.5 µg/mL; A5: RALP : RB at 62.5:62.5 µg/mL; A6: RALP : RB at 62.5:31.3 µg/
mL. Cell morphology was observed using a light microscope. B: Survival rate (P > 0.05). MDA-MB-231 cells were collected 48 h af-
ter adding RALP at 31.3, 62.5 µg/mL and/or RB at 62.5 µg/mL respectively. The trypan blue exclusion assay was used to determine
viable and total cell numbers. C: Secretion of AQP1. MDA-MB-231 cells were collected 72 h after the administration of RALP at
62.5 µg/mL and/or RB at 62.5 µg/mL. The concentration of AQP1 was measured using AQP1 enzyme-linked immunosorbent as-
say kit and expressed as the secretion of AQP1 every 1 × 104 cells. Comparedwith the control group, aP< 0.001; comparedwith RALP
62.5 groups, bP < 0.001. RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi (Radix Aconiti Lateralis Praeparata); AQP: aquaporin.
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Figure 5 Effects of Tubeimu (Rhizoma Bolbostemmatis) and / or Fuzi (Radix Aconiti Lateralis Praeparata) treatment on apoptosis and
cell cycle distribution
A: MDA-MB-231 cells were seeded and collected 48 h after adding RB at 31.3, 62.5 µg/mL and / or RALP at 62.5 µg/mL. As2O3 was
used as a positive control. Cells were stained with FITC Annexin V and PI respectively. Apoptosis were analyzed by flow cytometr.
B: SKBR3 cells were seeded and collected 48 h after adding RB at 31.3, 62.5 µg/mL and/or RALP at 62.5 µg/mL. Cells were stained
with FITC Annexin V and PI respectively. Apoptosis were analyzed by flow cytometr. Compared with the control group, aP < 0.001;
compared with AS2O3 group, bP < 0.05; compared with AS2O3 group, cP < 0.01; compared with RALP (62.5, 31.3) groups, dP <
0.001; compared with RB (62.5) group, eP < 0.05; compared with RB (62.5) group, fP < 0.001. RB: Tubeimu (Rhizoma Bolbostemma-
tis), RALP: Fuzi (Radix Aconiti Lateralis Praeparata).
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fects on cell migration compared with either tubeimo-
side I or acetylbenzoylaconine alone. Furthermore, the
inhibitory effect on cell migration of combined tubei-
moside I and acetylbenzoylaconine in SKBR3 cells was
superior to that in MDA-MB-231 cells, which is con-
sistent with the experimental results using aqueous ex-
tracts (Figure 7).
To determine whether Tubeimu (Rhizoma Bolbostem-
matis) and Fuzi (Radix Aconiti Lateralis Preparata) have
effects on epithelial adhesion molecules and the cyto-
skeleton of SKBR3 cells, we studied the expression of
E-cadherin, and localization and configuration of actin
filaments. In control cells, actin filaments were distrib-
uted in the cytoplasm and accumulated at ruffled cell
membranes, accompanied by decreased E-cadherin ex-
pression levels. Cells treated with Fuzi (Radix Aconiti
Lateralis Preparata) displayed pseudopodia formation
in which actin filaments preferentially accumulated at
the leading edge of ruffled cell membranes to form la-
mellipodia and the expression of E-cadherin was less
than that in control cells. However, cells treated with
Tubeimu (Rhizoma Bolbostemmatis) showed polymer-
ization and reorganization of actin filaments along the
cell membrane and in the cytoplasm, accompanied by
an increased expression of E-cadherin (P < 0.01). After
combined treatment with Tubeimu (Rhizoma Bolb-
ostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata)
at concentrations of 62.5∶62.5 µg/mL and 62.5∶31.3
µg/mL, cells changed into a polygonal shape and dis-
played decreased membrane ruffles. Actin filaments
were mainly localized in the cytoplasm and an addition-
al increase in E-cadherin expression level was observed
(P < 0.001) (Figure 8).
DISCUSSION
TCM has advocated combinatory therapeutic strate-
gies for more than 2500 years. Guided by the theories
of TCM, formulae are designed with a combination of
different plants or minerals to increase therapeutic effi-
cacy and decrease adverse effects. Examples include Re-
algar-Indigo naturalis formula and PHY906, whose ef-
ficacies in treating cancer have been established.1,2
WRCP, a Chinese medical formula that we previously
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Figure 6 Effects of Tubeibu (Rhizoma Bolbostemmatis) and /or
Fuzi (Radix Aconiti Lateralis Praeparata) treatment on cell mi-
gration byWound- healing assay
A-L: The photos of Wound-healing assay (400× ). SKBR3 cells
were treated with different drugs of DMEM medium (A and C),
RB at 62.5 µg/mL (B and D), RALP at 62.5 µg/mL (E and G),
RALP∶RB at 62.5∶62.5 µg/mL (F and H), RALP at 31.3 µg/mL (I
and K), RALP∶RB 62.5:31.3 µg/mL (J and L) respectively. Cell
migration was observed under a phase-contrast microscope
at 0 h (A, B, E, F, I, J) and 12 h (C, D, G, H, K, L) after exposure to
drugs. M: The statistical results of wound-healing assay were
expressed as the spacing of scarification. Compared with the
control group, aP<0.01; comparedwithRALP (62.5, 31.3) groups,
bP < 0.001; compared with the RB (62.5) group, cP < 0.001; com-
pared with the RALP:RB (62.5:62.5) group, dP < 0.001.
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designed, has demonstrated direct anti-cancer effects
on both hepatoma cells in vitro and breast cancer cells
in vivo.3,4 In this study, we used Fuzi (Radix Aconiti
Lateralis Preparata) and Tubeimu (Rhizoma Bolbostem-
matis) to investigate the synergistic effects of herbs and
the rationale of the formula on breast cancer cells.
The median effect principle can quantitatively define
antagonism, additive effects, and synergism in drug
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Figure 7 Effects of Tubeimu (Rhizoma Bolbostemmatis) and/or Fuzi (Radix Aconiti Lateralis Praeparata) treatment on cell migra-
tion by Transwell assay
A: transwell assay. After serum-starved for 24 h SKBR3 cells were treated with RB at 62.5 µg/mL, and/or RALP at 62.5 or 31.3 µg/
mL for 12 h. Cells that penetrated through the chamber were fixed, stained with crystal violet (0.1%), and counted using a light
microscope. B: MDA-MB-231 cells. The group, drug dose and method were same as those of A. Compared with the control
group, aP < 0.01; compared with RALP (62.5, 31.3) groups, bP < 0.001; compared with the control group, cP < 0.05; compared with
the RB (62.5) group, dP < 0.01; compared with the control group, eP < 0.001. RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi
(Radix Aconiti Lateralis Praeparata). C: SKBR3 cells. after serum-starved for 24 h SKBR3 cells were treated with T at 3 µg/mL, and/
or A at 3 or 1.5 µg/mL for 12 h. Cells that penetrated through the chamber were fixed, stained with crystal violet (0.1%), and
counted using a light microscope. D-E: The method was same as that of C. D: The administration of drugs was T at 5 µg/mL and/
or A at 5 or 2.5 µg/mL. E: The administration of drugs was A at 10 µg/mL, T at 10 µg/mL, T: A at 10∶10 µg/mL or 10∶5 µg/mL re-
spectively. F-I: MDA-MB-231 cells. The method was same as that of A. F: The administration of drugs was T at 3 µg/mL and/or A
at 3 or 1.5 µg/mL. G: The administration of drugs was T at 5 µg/mL and/or A at 5 or 2.5 µg/mL. H: The administration of drugs
was T at 7 µg/mL and/or A at 7 or 3.5 µg/mL. I: The administration of drugs was T at 10 µg/mL and/or A at 10 or 5 µg/mL. Com-
pared with the control group, aP < 0.01; compared with A(3) groups, bP < 0.01; compared with the T(3) group, cP < 0.01; com-
pared with the A∶T (3∶3) group, dP < 0.05; compared with the control group, eP < 0.05; compared with the A (5, 2.5) group, fP <
0.001; compared with the T (5) group, gP < 0.05; compared with the control group, hP < 0.001; compared with the A(5, 10) group,
iP < 0.001; compared with the T(3) group, jP < 0.05; compared with the control group, kP < 0.001; compared with the T (5) group,
lP < 0.001; compared with the A (7, 3.5) group, mP < 0.001. T: tubeimoside I, A: acetylbenzoylaconine.
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combinations and is widely used in drug combination
studies. Therefore, we used the median effect principle
to test the possible synergistic effects of Fuzi (Radix
Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bol-
bostemmatis) on breast cancer cell proliferation. Assess-
ment of the CI value by the median-effect method di-
rectly demonstrates the synergistic inhibitory effect of
Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu
(Rhizoma Bolbostemmatis) on the proliferation of breast
cancer cell lines MDA-MB-231 and SKBR3. We fur-
ther tested whether Tubeimu (Rhizoma Bolbostemmatis)
plus Fuzi (Radix Aconiti Lateralis Preparata) could act
on cell cycle progression and found that their combina-
tion caused G1 blockage of MDA-MB-231 cells.
Tubeimu (Rhizoma Bolbostemmatis) down-regulated
cell migration, while Fuzi (Radix Aconiti Lateralis Pre-
parata) up-regulated migration. Concomitant treat-
ment with Fuzi (Radix Aconiti Lateralis Preparata) and
Tubeimu (Rhizoma Bolbostemmatis) down-regulated
cell migration. These observations are in agreement
with the rationality of the formula, which is mutual re-
inforcement of the compounds and reduction in ad-
verse effects. Moreover, cell migration was detected at
12 h after drug treatment at the time at which cytotox-
icity or inhibitory effects on cell proliferation was not
observed (data not shown). Therefore, the synergistic
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Figure 8 Effects of Tubeimu (Rhizoma Bolbostemmatis) and/or Fuzi (Radix Aconiti
Lateralis Praeparata) on E-cadherin and actin filaments
A. E-cadherin. A1: After serum-starved for 24 h, 1×105 cells/well SKBR3 cells were
seeded and divided into the drug treatment groups as follows. A1-1: control
group; A1-2: 62.5 µg/mL RALP group, A1-3: 62.5 µg/mL RB group, A1-4: RALP:RB
group (62.5∶62.5 µg/mL); A1-5: RALP: RB group (62.5∶31.3 µg/mL). After twelve
hours, cells were incubated with antibody against E-cadherin(1∶100) for 16 h at
4 ℃ , followed by fluorescence-conjugated secondary antibody (1∶5000) at room
temperature for 1 h and then examined using a confocal microscope (×400). A2:
The statistical results of the fluorescence of E-cadherin as integral optical density.
Compared with the control group, aP < 0.01; compared with the RALP (62.5)
group, bP < 0.001; compared with the RB (62.5) group, cP < 0.001; compared with
the RALP∶RB. B. actin filaments SKBR3 cells cells cultured on coverslips were treat-
ed with different drugs as follows. B1: control group; B2: 62.5 µg/mL RALP group,
B3: 31.3 µg/mL RALP group; B4: 62.5 µg/mL RB group; B5: RALP∶RB group (62.5∶
62.5 µg/mL); B6: RALP∶RB group (62.5∶31.3 µg/mL). Twelve hours later, cells were
incubated with 2-µg/mL phalloidin rhodamine at 4℃ overnight, followed by stain-
ing with 4′,6-diamidino-2-phenylindole (1 µg/mL) and examined using a confocal
microscope (× 600). RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi (Radix
Aconiti Lateralis Praeparata).
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inhibitory effect on cell migration was not because of
the cytotoxicity or proliferation inhibition effect of
drugs.
Cell adhesion and migration are interdependent cellu-
lar processes whose alterations lead to the acquisition
of a more motile phenotype by cancer cells, allowing
for tumor migration. Decreased expression of the epi-
thelial adhesion molecule E-cadherin plays a key role
in the acquisition of the invasive phenotype of many
tumors. The cytoskeleton provides the basic infrastruc-
ture for the maintenance of cell motility.15 Tumor cell
migration depends mainly on the polymerization and
reorganization of actin filaments. The formation of dis-
tinct actin-based membrane protrusions at the cell
front, such as lamellipodia, is at the core of this pro-
cess.16 By generating both pushing and contractile forc-
es, actin filaments are capable of promoting cell motili-
ty.17 SKBR3 cells treated with Fuzi (Radix Aconiti Later-
alis Preparata) presented a decreased expression of
E-cadherin and accumulated actin filaments at the lead-
ing edge of ruffled cell membranes to form protrusions
relative to control cells. However, SKBR3 cells treated
with Tubeimu (Rhizoma Bolbostemmatis) in combina-
tion with Fuzi (Radix Aconiti Lateralis Preparata)
showed an increased expression of E-cadherin and reor-
ganization of actin filaments in the cytoplasm along
with decreased formation of membrane ruffles relative
to cells treated with Tubeimu (Rhizoma Bolbostemma-
tis) alone.
Aquaporins are one type of membrane protein that reg-
ulate water transport across the cell membrane. The ele-
vated expression of aquaporin-1 (AQP1) assists water
uptake and can result in a cell swelling phenotype.18,19
Tubeimoside 1, a triterpenoid saponin extracted from
Tubeimu (Rhizoma Bolbostemmatis), is cytotoxic in sev-
eral human cancer cell lines.11, 20-23 However, in trypan
blue exclusion assay, combined treatment with Fuzi
(Radix Aconiti Lateralis Preparata) and Tubeimu (Rhi-
zoma Bolbostemmatis) did not increase cytotoxicity
when compared with Tubeimu (Rhizoma Bolbostemma-
tis) alone, which is partly because there were no chang-
es in the expression of AQP1. The apoptotic percent-
age of MDA-MB-231 cells treated with Fuzi (Radix
Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bol-
bostemmatis) was also much higher than those from
Fuzi (Radix Aconiti Lateralis Preparata) or Tubeimu
(Rhizoma Bolbostemmatis) alone. Because the apoptotic
bodies were free from trypan blue dyeing, the synergis-
tic effect on inducing cell apoptosis was observed but
no difference in viability was observed.
Acetylbenzoylaconine and tubeimoside Ⅰ, the major
active ingredients of Tubeimu (Rhizoma Bolbostemma-
tis) and Fuzi (Radix Aconiti Lateralis Preparata), were
previously shown to inhibit proliferation and induce
apoptosis in several cancer cell lines.8-11 Our results
show that acetylbenzoylaconine plus tubeimoside Ⅰ
exhibited a synergistic inhibitory effect on cell prolifera-
tion and migration, which was consistent with the re-
sults of the aqueous extracts. However, the promotion
effect on cell migration of acetylbenzoylaconine was
not observed, which is because not all active ingredi-
ents from Fuzi (Radix Aconiti Lateralis Preparata) were
tested, such as mesaconitine and hypaconitine.
In conclusion, our findings demonstrate that the inhib-
itory effects of Tubeimu (Rhizoma Bolbostemmatis) on
the proliferation and migration of cell line
MDA-MB-231 and SKBR3 are enhanced when used
with Fuzi (Radix Aconiti Lateralis Preparata) extract.
Furthermore, the promotion effect of Fuzi (Radix Acon-
iti Lateralis Preparata) extract on the migration of
MDA-MB-231 and SKBR3 cells was reduced when
combined with Tubeimu (Rhizoma Bolbostemmatis).
We further demonstrated that acetylbenzoylaconine
and tubeimoside I acted as the essential components in
the extracts of Fuzi (Radix Aconiti Lateralis Preparata)
and Tubeimu (Rhizoma Bolbostemmatis), exerting syner-
gistic effects on MDA-MB-231 and SKBR3 cells.
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